IL282820A - Genetically engineered embryonic mesenchymal cells overexpressing AOAH and their uses - Google Patents

Genetically engineered embryonic mesenchymal cells overexpressing AOAH and their uses

Info

Publication number
IL282820A
IL282820A IL282820A IL28282021A IL282820A IL 282820 A IL282820 A IL 282820A IL 282820 A IL282820 A IL 282820A IL 28282021 A IL28282021 A IL 28282021A IL 282820 A IL282820 A IL 282820A
Authority
IL
Israel
Prior art keywords
aoah
genetically
stem cells
mesenchymal stem
cells overexpressing
Prior art date
Application number
IL282820A
Other languages
English (en)
Hebrew (he)
Inventor
Michael Callahan
Shirley H J Mei
Yan Wang
Maria Florian
Katelynn Rowe
Chyan-Jang Lee
Original Assignee
Ottawa Hospital Res Inst
United Therapeutics Corp
Michael Callahan
Shirley H J Mei
Yan Wang
Maria Florian
Katelynn Rowe
Lee Chyan Jang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ottawa Hospital Res Inst, United Therapeutics Corp, Michael Callahan, Shirley H J Mei, Yan Wang, Maria Florian, Katelynn Rowe, Lee Chyan Jang filed Critical Ottawa Hospital Res Inst
Publication of IL282820A publication Critical patent/IL282820A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01077—Acyloxyacyl hydrolase (3.1.1.77)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL282820A 2018-10-29 2021-04-29 Genetically engineered embryonic mesenchymal cells overexpressing AOAH and their uses IL282820A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862752000P 2018-10-29 2018-10-29
PCT/CA2019/051526 WO2020087160A1 (en) 2018-10-29 2019-10-29 Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof

Publications (1)

Publication Number Publication Date
IL282820A true IL282820A (en) 2021-06-30

Family

ID=70462996

Family Applications (1)

Application Number Title Priority Date Filing Date
IL282820A IL282820A (en) 2018-10-29 2021-04-29 Genetically engineered embryonic mesenchymal cells overexpressing AOAH and their uses

Country Status (10)

Country Link
US (1) US20220010281A1 (cg-RX-API-DMAC7.html)
EP (1) EP3874029B1 (cg-RX-API-DMAC7.html)
JP (1) JP7372982B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210086662A (cg-RX-API-DMAC7.html)
CN (1) CN113166729A (cg-RX-API-DMAC7.html)
AU (1) AU2019370629A1 (cg-RX-API-DMAC7.html)
ES (1) ES2962812T3 (cg-RX-API-DMAC7.html)
IL (1) IL282820A (cg-RX-API-DMAC7.html)
SG (1) SG11202103509RA (cg-RX-API-DMAC7.html)
WO (1) WO2020087160A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL302060A (en) * 2020-10-16 2023-06-01 Ottawa Hospital Res Inst Cell-based therapy for viral diseases
CN116570711A (zh) * 2022-12-21 2023-08-11 上海交通大学医学院附属第九人民医院 酰基羧酸水解酶在制备治疗肾脏纤维化疾病的药物中的应用
WO2026101889A2 (en) * 2024-11-06 2026-05-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Acyloxyacyl hydrolase and methods of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
US5281520A (en) * 1990-09-12 1994-01-25 Zymogenetics, Inc. Method for producing acyloxyacyl hydrolase
CN101378764A (zh) * 2005-12-09 2009-03-04 贝勒研究院 通过血液白细胞微阵列分析对系统性红斑狼疮的诊断、预后和疾病发展的监测
JP2011528566A (ja) * 2008-07-21 2011-11-24 コンプジェン リミティッド アンジオポエチン由来ペプチド
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
JP2012529895A (ja) * 2009-06-19 2012-11-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗egfr抗体の癌療法における有効性を決定するためのバイオマーカーおよび方法
EP2626369A1 (en) * 2011-11-24 2013-08-14 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Engineered mesenchymal stem cells and their therapeutic use
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
RU2658490C2 (ru) * 2012-03-27 2018-06-21 Кьюрвак Аг Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов
CA2928852A1 (en) * 2013-11-01 2015-05-07 Regeneron Pharmaceuticals, Inc. Angiopoietin-based interventions for treating cerebral malaria
WO2015090229A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
KR102213527B1 (ko) * 2014-06-30 2021-02-09 타이제닉스, 에스.에이.유. 패혈증 치료용 중간엽 기질세포
PL3242933T3 (pl) * 2015-01-08 2019-08-30 Apceth Gmbh & Co. Kg Zmodyfikowane genetycznie mezenchymalne komórki macierzyste wykazujące ekspresję alfa-1 antytrypsyny (aat)
CA3172801A1 (en) * 2015-06-12 2016-12-15 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
CN108430480B (zh) * 2015-09-15 2022-08-02 康干细胞生物科技有限公司 一种包含过表达sod3的干细胞作为活性成分的炎症性疾病的预防或治疗用组合物

Also Published As

Publication number Publication date
AU2019370629A1 (en) 2021-05-20
WO2020087160A1 (en) 2020-05-07
EP3874029A1 (en) 2021-09-08
ES2962812T3 (es) 2024-03-21
EP3874029B1 (en) 2023-08-30
KR20210086662A (ko) 2021-07-08
CN113166729A (zh) 2021-07-23
US20220010281A1 (en) 2022-01-13
EP3874029A4 (en) 2022-08-03
JP2022513379A (ja) 2022-02-07
JP7372982B2 (ja) 2023-11-01
CA3116196A1 (en) 2020-05-07
SG11202103509RA (en) 2021-05-28

Similar Documents

Publication Publication Date Title
IL287553A (en) Modified pluripotent cells
IL285619A (en) Universal donor stem cells and related methods
IL277025A (en) Methods for improving the differentiation of stem cells into beta cells
SG11202101994XA (en) Genetically engineered hematopoietic stem cells and uses thereof
IL267616A (en) Immunologically engineered pluripotent cells
IL275037A (en) CRISPR-CAS9-modified CD34+ human hematopoietic stem and progenitor cells and uses thereof
IL281171A (en) Cellulose-synthase-like enzymes and their uses
SG10201705182RA (en) Method of distinguishing mesenchymal stem cells and method of determining purity of mesenchymal stem cells
GB201819540D0 (en) T cell modification
IL263265A (en) Use of mesenchymal stem cells and their parts
EP3866816A4 (en) EXOSOMES FROM MESENCHYMATOUS STEM CELLS AND METHODS
SG11202107732XA (en) Dorsally-derived oligodendrocyte progenitor cells from human pluripotent stem cells
ES2948810T8 (en) Method for obtaining an enriched population of functional mesenchymal stem cells, cells obtained thereof and compositions comprising the same
IL255480B (en) Preparations containing mesenchymal stem cells and their uses
EP3886880C0 (en) METHODS AND APPARATUS FOR OBTAINING AMNIOTIC MESENCHYMATOUS STEM CELLS FROM AMNIOTIC FLUID AND CELLS DERIVED THEREOF
EP4034172A4 (en) GENETICALLY MODIFIED MESENCHYMATOUS STEM CELLS AND THEIR APPLICATIONS
IL268194B (en) Environment and methods to increase survival and proliferation of embryo cells
GB201701509D0 (en) Pluripotenet stem cells
IL253063A0 (en) Genetically modified mesenchymal stem cells expressing alpha-1 antitrypsin (aat)
IL281153A (en) Direct differentiation of a urinary cell into a neural stem cell using artificial mRNA
IL290109A (en) Cells for enhanced immune healing and their uses
SG11202103509RA (en) Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof
SG11202005509YA (en) Recombinant adenoviruses and stem cells comprising same
EP3865571C0 (en) SYNOVIAL-DERIVED MESENCHYMAL STEM CELLS AND THEIR USE
IL281751A (en) Methods for inducing differentiation in mesenchymal stem cells